Pfizer cuts 2022 earnings outlook despite strong first-quarter Covid vaccine and antiviral sales

Pfizer said it sold $13.2 billion of its Covid vaccine and $1.5 billion of its antiviral treatment Paxlovid.

Previous post Fears of a Fed mistake grow as this week’s anticipated interest rate hike looms
Next post S&P 500 rises slightly in choppy trading ahead of Fed decision